Intensity Therapeutics (INTS) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed Senti Biosciences (SNTI) over the past year, losing 48.4% versus a loss of 81.9%. Intensity Therapeutics is the larger company by market cap ($12.0 million vs $10.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | SNTI |
|---|---|---|
| Share price | $3.68 | $0.3217 |
| Market cap | $12.01M | $10.02M |
| 1-day change | -3.16% | -2.52% |
| YTD return | -64.10% | -69.07% |
| 1-year return | -48.35% | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-3.89 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $2.88 |
| 52-week low | $3.21 | $0.29 |
| Distance from 52-week high | -91.54% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +425.27% | +4096.46% |
| Average volume | 25.93K | 573.78K |
| Shares outstanding | 3.26M | 31.15M |
| Employees | 5 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INTS has outperformed SNTI by 33.6 percentage points over the past year.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
INTS vs SNTI FAQ
Which is bigger, Intensity Therapeutics or Senti Biosciences?
Intensity Therapeutics (INTS) is larger, with a market capitalization of $12.01M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, INTS or SNTI?
INTS returned -48.35% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.